Aim To investigate the effects of Amaryl on newly diagnosed type2 diabetes. Methods 33 newly diagnosed type 2 diabetic patients with fasting plasma glucose (FPG)<12 mmol/L were treated with Amaryl for 12 weeks. Oral glucose tolerance test (OGTT) was performed before and after Amaryl therapy. The fasting and post 2 h plasma glucose (P2hPG), hemoglobin A1C (GHbA1C), Homa-IR, TC, TG, LDLC, HDLC, tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were compared before and after Amaryl. Results After 2 weeks′Amaryl treatment, good glycemic control was achieved. The FPG, P2hPG, GHbA1C, TC, TG, LDLC, Homa-IR, tPA were lower than before.But HDLC, PAI-1 were higher than before. Conclusion Excellent glycemic controls, improvements of lipid profiles and PAI-1 and decreased insulin resistence can be induced by Amary therapy in newly diagnosed type 2 diabetic patients.